Peptide And Oligonucleotide CDMO Market Size & Share Analysis - Growth, Trends And Forecasts (2025 - 2030)

The Peptide and Oligonucleotide CDMO Market Report is Segmented by Product (Peptide CDMO, Oligonucleotide CDMO, and More), Application (Therapeutics, Diagnostics, and More), Service Type (Process Development, GMP Manufacturing, and More), End User (Pharmaceutical & Biotechnology Companies, and More), and Geography (North America, Europe, Asia Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Peptide And Oligonucleotide CDMO Market Size and Share

Peptide And Oligonucleotide CDMO Market Summary
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Peptide And Oligonucleotide CDMO Market Analysis by Mordor Intelligence

The Peptide and Oligonucleotide CDMO market is valued at USD 2.68 billion in 2025 and is forecast to reach USD 4.66 billion by 2030, registering an 11.7% CAGR over the period. Supply-demand imbalance, highlighted by ongoing shortages in GLP-1 receptor agonists and siRNA therapeutics, has repositioned contract development and manufacturing organizations (CDMOs) from niche partners to critical nodes in the pharmaceutical value chain. Capital-intensive expansions such as CordenPharma’s EUR 900 million (USD 1.05 billion) upgrade in Switzerland signal an industry scrambling to alleviate capacity bottlenecks while simultaneously navigating sustainability pressures from solvent-intensive peptide synthesis. Regionally, North America remains the revenue anchor, yet Asia Pacific’s low-cost manufacturing base and aggressive buildouts by WuXi STA and Samsung Biologics are redrawing competitive maps. Product complexity is rising as multimodal, peptide-oligonucleotide conjugates move from research to clinic, demanding new analytical expertise and pushing CDMOs toward end-to-end service models that include process development, fill-finish, and regulatory support.

Key Report Takeaways

  • By product, peptide CDMO services led with a 55.6% revenue share in 2024, while peptide-oligonucleotide conjugate services are projected to expand at a 16.5% CAGR to 2030. 
  • By application, therapeutics held 72.1% of the Peptide And Oligonucleotide CDMO market share in 2024; gene-editing applications record the highest forecast CAGR at 15.2% through 2030. 
  • By service type, GMP manufacturing commanded 61.5% of the Peptide and Oligonucleotide CDMO market size in 2024, whereas fill-finish and packaging are advancing at a 14.6% CAGR to 2030. 
  • By end user, pharmaceutical and biotechnology companies accounted for a 68.3% revenue share in 2024; gene and cell therapy developers are growing at a 14.3% CAGR through 2030. 
  • By geography, North America retained 38.8% of the market share in 2024, while Asia Pacific is the fastest-growing region, with a 13.4% CAGR through 2030.

Segment Analysis

By Product: Peptide Dominance Faces Conjugate Disruption

Peptide CDMO services generated 55.6% revenue in 2024, reflecting mature infrastructure and validated regulatory pathways. Oligonucleotide contracts occupy a growing midpoint, but the fastest-rising opportunity lies in peptide-oligonucleotide conjugate manufacturing, forecast at a 16.5% CAGR. The Peptide and Oligonucleotide CDMO market size for conjugate services is projected to widen sharply as sponsors chase multimodal delivery advantages tied to precision medicine. Leaders such as Bachem leverage half-century know-how, while newer entrants carve niches by linking state-of-the-art solid-phase peptide synthesis with high-throughput oligo chemistry suites.

Manufacturing convergence creates high technical hurdles. Processes must reconcile divergent solvent systems, deprotection chemistries, and analytical release criteria. Few facilities can manage in-line conjugation at scale, making capacity scarce and margins attractive. CDMOs with frontline regulatory dialogue and dual-competency staff win early-stage programs that later convert into long-term commercial contracts, reinforcing a virtuous capacity-utilization cycle.

Peptide And Oligonucleotide CDMO Market: Market Share by Product
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Application: Therapeutics Leadership Yields to Gene Editing Growth

Therapeutics contracts delivered 72.1% of 2024 revenue, buoyed by chronic disease indications that require sustained supply volumes. Yet the Peptide And Oligonucleotide CDMO market is pivoting swiftly: gene-editing applications will outpace all others at a 15.2% CAGR through 2030, underpinned by CRISPR-Cas9 pipelines needing guide RNA and peptide-based delivery vectors. The resulting diversification reduces reliance on traditional metabolic disease franchises and stabilizes the project mix across therapeutic areas.

Emerging indications drive specialized analytical validation such as off-target editing assays—that further entrench CDMOs able to integrate multidisciplinary QC workflows. Sponsors reward such breadth with multi-year master service agreements, insulating preferred partners from commoditization pressures and price erosion that historically plagued mature therapeutics supply categories.

By Service Type: GMP Manufacturing Dominance Challenged by Fill-Finish Growth

GMP manufacturing supplied 61.5% of segment revenue in 2024, cementing its role as the Peptide and Oligonucleotide CDMO market’s economic bedrock. However, fill-finish and packaging are the fastest-growing offerings at 14.6% CAGR, reflecting downstream constraints that now bottleneck launch schedules. Integrated providers that couple synthesis with specialized aseptic vialing or autoinjector filling offer one-stop solutions attractive to lean biotech teams.

This evolution elevates capital expenditure on isolator technology, lyophilization suites, and cold-chain infrastructure, but also strengthens customer lock-in by embedding CDMOs deep into the final-product value stream. The Peptide And Oligonucleotide CDMO market share commanded by pure-play development shops is expected to erode as full-service peers capture lifecycle value from IND through commercial supply.

Peptide And Oligonucleotide CDMO Market: Market Share by Service Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Pharma Dominance Faces Gene Therapy Disruption

Pharmaceutical and biotechnology enterprises retained 68.3% of 2024 contract value due to blockbuster GLP-1 scale-ups. Yet the fastest expansion comes from gene and cell therapy developers, projected at 14.3% CAGR. These ventures require bespoke oligonucleotide payloads, high-purity peptides for delivery, and regulatory documentation tuned for autologous workflows, all of which push CDMOs to customize batch sizes and qualification protocols.

Sponsors value partners that can flex between gram-scale research lots and multi-kilogram commercial campaigns without tech transfer delays. Consequently, CDMOs investing in modular cleanrooms and single-use equipment gain agility advantages that resonate with venture-backed clients operating on milestone-driven financing.

By Scale: Commercial Services Lead Despite Clinical Growth

Commercial-scale work captured 52.7% of the 2024 turnover, underscoring long-duration, high-volume supply agreements for marketed peptides and oligonucleotides. Yet early-phase clinical support will outstrip all other scales at a 13.9% CAGR to 2030, propelled by venture-capital funding cycles that prize quick proof-of-concept data. The Peptide And Oligonucleotide CDMO market size tied to phase I–II projects is poised to expand in parallel with record biotech IPO pipelines.

Early-stage contracts often feature higher per-gram margins, but they also demand rapid tech transfer and flexible scheduling. CDMOs that master phase-appropriate validation and can rapidly pivot suites between client projects will capture a disproportionate share of this high-growth revenue pool.

Geography Analysis

North America’s 38.8% share in 2024 reflects entrenched pharma ecosystems, FDA familiarity, and a network of multi-modal innovation hubs. Recent multiyear capacity commitments from Thermo Fisher exemplify how proximity and regulatory competence offset higher operating costs. Yet scaling challenges persist: energy prices, solvent-disposal regulations, and skilled-labor shortages escalate the total cost of ownership, prompting sponsors to reassess regional sourcing strategies in favor of blended North America–Asia portfolios.

Asia Pacific is rewriting competitive baselines. Samsung Biologics’ fifth plant and WuXi STA’s Taixing peptide campus illustrate a surge of capital exceeding USD 2 billion across South Korea and China alone. Lower unit costs, government incentives, and increasingly FDA-audited facilities are eroding historical perceptions of quality gaps. As patent cliffs squeeze pricing on chronic-disease therapeutics, these economics will pull a larger slice of volume production eastward, even as complex early development work remains in the West.

Europe leverages deep regulatory integration and a concentration of legacy peptide expertise to protect share in high-value, low-volume projects. Switzerland’s dual anchors—Bachem and CordenPharma—serve as cluster magnets, attracting ancillary suppliers and academic collaborations that reinforce regional dominance in ultra-high-purity synthesis. However, environmental legislation that tightens solvent-emission caps is accelerating capex requirements, compelling European CDMOs to adopt continuous-flow technologies sooner than peers elsewhere.

Peptide And Oligonucleotide CDMO Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Competition is moderate and revolves around capacity access rather than price. Incumbents such as Bachem, PolyPeptide Group, and Thermo Fisher preserve leadership via multi-decade regulatory track records, proprietary process know-how, and strategic geographic footprints. Seller-market dynamics prevail: clients routinely accept volume-reservation premiums to guarantee launch timelines. Asian peers—Samsung Biologics, WuXi STA and SK pharmteco—are expanding aggressively, leveraging cost economics and scale to win commercial batch contracts, pressuring Western CDMOs to emphasize technology leadership and service breadth.

Strategic differentiation is shifting from single-service proficiency to end-to-end offerings. Lonza, Catalent (post-Novo Holdings) and Samsung Biologics now pitch cradle-to-commercial packages spanning cell-line development, conjugation, fill-finish and serialization. Technology races center on continuous-flow reactors, AI-driven sequence design and solvent-recycling platforms that cut cost of goods while meeting tightening ESG standards. White-space opportunities persist in conjugate GMP suites and cold-chain fill-finish capacity—areas where demand outstrips supply and entry barriers remain high.

M&A momentum continues as scale and integrated capabilities become prerequisites for preferred-supplier status. Mega-deals (e.g., Catalent, BIOVECTRA) and focused tuck-ins (e.g., PCI’s fill-finish acquisitions) signal a consolidation cycle that will reshape vendor lists over the next five years, likely boosting the Peptide and Oligonucleotide CDMO market’s average contract value and increasing switching costs for sponsors.

Peptide And Oligonucleotide CDMO Industry Leaders

  1. Thermo Fisher Scientific Inc.

  2. Polypeptide Group

  3. Wuxi Apptec Co., Ltd.

  4. Genscript Biotech Corporation

  5. CordenPharma International

  6. *Disclaimer: Major Players sorted in no particular order
Peptide And Oligonucleotide CDMO Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • April 2025: Samsung Biologics began operations at Plant 5, adding 180,000 L capacity and opening a dedicated ADC facility, alongside a USD 1.4 billion CDMO contract with a European pharma company.
  • March 2025: Merck KGaA reported 2024 Life Science Services revenue of EUR 722 million (USD 850 million) and unveiled investments in ADC and bioprocessing capacity.
  • January 2025: Samsung Biologics signed a USD 1.4 billion manufacturing agreement with a European client at the Songdo campus, which will extend through 2030.
  • December 2024: Novo Holdings finalized its USD 16.5 billion acquisition of Catalent, creating vertically integrated peptide and oligonucleotide supply solutions.

Table of Contents for Peptide And Oligonucleotide CDMO Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Surging GLP-1 & SiRNA Clinical Pipeline Is Straining Global GMP Capacity
    • 4.2.2 Growing Demand For Peptide-/ASO-Enabled Precision Medicines
    • 4.2.3 Shift Toward Outsourcing By Big Pharma & VC-Backed Biotechs
    • 4.2.4 Continuous-Flow Synthesis Platforms Slash COGS & Waste
    • 4.2.5 Near-Term Launch Of Self-Administered Oral Peptides Boosts CDMO Volumes
    • 4.2.6 AI-Driven Peptide And Oligo Sequence Optimization Accelerates Candidate Turnover
  • 4.3 Market Restraints
    • 4.3.1 Chronic Talent Shortage In Large-Scale Downstream Purification
    • 4.3.2 Regulatory Harmonisation Lags For Hybrid Peptide-Oligo Conjugates
    • 4.3.3 Global Solvent-Recycling Mandates Add Capex Pressure
    • 4.3.4 Limited Supply Of Protected Nucleoside Phosphoramidites
  • 4.4 Supply Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value)

  • 5.1 By Product
    • 5.1.1 Peptide CDMO
    • 5.1.2 Oligonucleotide CDMO
    • 5.1.3 Peptide-Oligonucleotide Conjugate CDMO
  • 5.2 By Application
    • 5.2.1 Therapeutics
    • 5.2.2 Diagnostics
    • 5.2.3 Research & Discovery
    • 5.2.4 Vaccines
    • 5.2.5 Gene Editing
  • 5.3 By Service Type
    • 5.3.1 Process Development
    • 5.3.2 GMP Manufacturing
    • 5.3.3 Analytical & Quality Control
    • 5.3.4 Fill-Finish & Packaging
    • 5.3.5 Regulatory & CMC Support
  • 5.4 By End User
    • 5.4.1 Pharmaceutical & Biotechnology Companies
    • 5.4.2 Academic & Research Institutes
    • 5.4.3 Diagnostic Companies
    • 5.4.4 Gene- & Cell-Therapy Developers
    • 5.4.5 Others
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
    • 6.3.1 Bachem Holding AG
    • 6.3.2 PolyPeptide Group
    • 6.3.3 Thermo Fisher Scientific (Patheon)
    • 6.3.4 Catalent Inc.
    • 6.3.5 Merck KGaA (MilliporeSigma)
    • 6.3.6 WuXi AppTec / STA
    • 6.3.7 Lonza
    • 6.3.8 Ajinomoto Bio-Pharma Services
    • 6.3.9 Asymchem Laboratories
    • 6.3.10 Siegfried AG
    • 6.3.11 CordenPharma International
    • 6.3.12 Eurogentec (Kaneka)
    • 6.3.13 GenScript Biotech
    • 6.3.14 Almac Group
    • 6.3.15 Integrated DNA Technologies
    • 6.3.16 Agilent Technologies
    • 6.3.17 Eurofins Genomics
    • 6.3.18 Senn Chemicals AG
    • 6.3.19 Rentschler Biopharma
    • 6.3.20 Novasep
    • 6.3.21 Samsung Biologics (Oligo Unit)
    • 6.3.22 Enzene Biosciences
    • 6.3.23 PharmaEssentia CDMO
    • 6.3.24 Biosynth
    • 6.3.25 AmideBio

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Peptide And Oligonucleotide CDMO Market Report Scope

As per the report's scope, peptides are short chains of amino acids, and oligonucleotides are short DNA or RNA molecules. In biotechnology and drug development, peptide oligonucleotides are used for various purposes, including gene therapy and diagnostics. CDMOs offer expertise in synthesis, purification, and other processes involved in manufacturing these molecules.

The peptide and oligonucleotide CDMO market is segmented by product, application, end user, and geography. The market is segmented by products, such as peptide CDMO and oligonucleotide CDMO. The market is segmented by application into therapeutics, research applications, diagnostics, and other applications. End user segments the market as pharmaceutical and biotechnology companies, research institutes, contract research organizations (CROs), and academic and government organizations. The market is segmented by geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.

By Product Peptide CDMO
Oligonucleotide CDMO
Peptide-Oligonucleotide Conjugate CDMO
By Application Therapeutics
Diagnostics
Research & Discovery
Vaccines
Gene Editing
By Service Type Process Development
GMP Manufacturing
Analytical & Quality Control
Fill-Finish & Packaging
Regulatory & CMC Support
By End User Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Diagnostic Companies
Gene- & Cell-Therapy Developers
Others
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product
Peptide CDMO
Oligonucleotide CDMO
Peptide-Oligonucleotide Conjugate CDMO
By Application
Therapeutics
Diagnostics
Research & Discovery
Vaccines
Gene Editing
By Service Type
Process Development
GMP Manufacturing
Analytical & Quality Control
Fill-Finish & Packaging
Regulatory & CMC Support
By End User
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Diagnostic Companies
Gene- & Cell-Therapy Developers
Others
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
South Korea
Australia
Rest of Asia Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the Peptide and Oligonucleotide CDMO market?

The Peptide and Oligonucleotide CDMO market is valued at USD 2.68 billion in 2025 and is projected to grow to USD 4.66 billion by 2030.

Which region is growing fastest for peptide and oligonucleotide outsourcing?

Asia Pacific registers the highest growth, with a 13.4% CAGR through 2030, driven by large-scale capacity additions and cost advantages.

Why are peptide-oligonucleotide conjugates gaining traction?

Conjugates combine peptide targeting with oligonucleotide therapeutic payloads, improving delivery efficiency and creating high-margin manufacturing demand that few CDMOs can meet.

What service segment is expanding quickest within CDMOs?

Fill-finish & packaging services are growing at a 14.6% CAGR as bottlenecks shift downstream and sponsors seek integrated end-to-end suppliers.

How are CDMOs addressing sustainability concerns in peptide synthesis?

Early adopters are rolling out continuous-flow manufacturing, which reduces solvent use by up to 80% and lowers carbon footprints, aligning with emerging ESG mandates.

Page last updated on: July 6, 2025

Peptide And Oligonucleotide CDMO Market Report Snapshots

Compare market size and growth of Peptide And Oligonucleotide CDMO Market with other markets in Healthcare Industry

OSZAR »